Promising early research by John Hopkins University and startup drug company AgeneBio successfully showed low dose treatment of AGB101 to lab animals, like rats, resulted in calmed over-activity in the brain and improved memory performance in subjects experiencing memory loss and considered pre-dementia.
Trial to Study AGB101 to Determine if it Can Slow Progression of Symptoms Associated with aMCI and Prevent or Delay Onset of Alzheimer’s Dementia Baltimore, MD, December 15, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the launch of the HOPE4MCI Phase 3 clinical trial website. Designed for…
Baltimore-based biopharmaceutical company AgeneBio has appointed Richard Mohs as vice president of clinical development. Mohs has more than 30 years of experience in neuroscience clinical development and led Eli Lilly’s Phase 3 development team for Alzheimer’s disease drug candidates solanezumab and semagacesta, AgeneBio noted in a statement Tuesday.
Eli Lilly Alzheimer’s Drug Development Veteran Rounds Out Leadership Team for Phase 3 Ready AGB101 Baltimore, MD, December 8, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the appointment of Alzheimer’s drug development veteran Richard Mohs, PhD, as Vice President of Clinical Development. Dr. Mohs offers more…
CEO Jerry McLaughlin will participate on a panel entitled, “Access to Medicine: Charities, Academics & Industry Collaboration for New Treatments,” on Thursday, December 3, at 3:45 pm Pacific Time.